Ascendis Pharma A/S reported earnings of $ 1.24 per ASND share on Nov 12, 2026, beating analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | $ 0.894 |
| Earnings Per Share (Surprise) | $ 1.24 (+$ 0.346) |
| Last Year's EPS | -$ 1.10 |
| EPS YoY Change |
Out of the last 55 earnings reporting periods, Ascendis Pharma A/S beat analysts’ expectations 22 times and fell short of expectations 24 time(s). Ascendis Pharma A/S reported earnings per share of $ 1.24 in the last report surpassing an estimated EPS of $ 0.894 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | $ 0.894 | $ 1.24 | -$ 1.17 | |
| Aug 13, 2026 | $ 1.71 | $ 3.29 | -$ 0.93 | |
| May 7, 2026 | $ 0.1876 | $ 0.32 | -$ 1.66 | |
| Feb 11, 2026 | -$ 0.06 | -$ 0.64 | -$ 0.68 | |
| Nov 12, 2025 | -$ 0.41 | -$ 1.17 | -$ 1.81 | |
| Aug 7, 2025 | -$ 1.42 | -$ 0.93 | -$ 2.05 | |
| May 1, 2025 | -$ 1.56 | -$ 1.66 | -$ 2.48 | |
| Feb 12, 2025 | -$ 1.20 | -$ 0.68 | -$ 1.66 | |
| Nov 14, 2024 | -$ 1.83 | -$ 1.81 | -$ 3.08 | |
| Sep 3, 2024 | -$ 1.54 | -$ 2.05 | -$ 2.35 | |
| May 2, 2024 | -$ 1.62 | -$ 2.48 | -$ 2.18 | |
| Feb 7, 2024 | -$ 2.19 | -$ 1.66 | -$ 3.96 | |
| Nov 7, 2023 | -$ 2.55 | -$ 3.08 | -$ 3.05 | |
| Sep 5, 2023 | -$ 2.68 | -$ 2.35 | -$ 1.50 | |
| Apr 27, 2023 | -$ 2.93 | -$ 2.18 | -$ 2.31 | |
| Feb 16, 2023 | -$ 2.74 | -$ 3.96 | -$ 2.06 | |
| Nov 2, 2022 | -$ 2.52 | -$ 3.05 | -$ 1.69 | |
| Aug 10, 2022 | -$ 2.19 | -$ 1.50 | -$ 3.01 | |
| May 11, 2022 | -$ 2.09 | -$ 2.31 | -$ 1.43 | |
| Mar 2, 2022 | -$ 2.57 | -$ 2.06 | -$ 3.15 |
Ascendis Pharma A/S’s stock was trading at $ 259.28 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, ASND’s price increased to $ 275.39 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | $ 1.24 | $ 259.28 | $ 275.39 | |
| Aug 13, 2026 | $ 3.29 | $ 255.46 | $ 248.50 | |
| May 7, 2026 | $ 0.32 | $ 235.90 | $ 238.66 | |
| Feb 11, 2026 | -$ 0.64 | $ 224.19 | $ 218.10 | |
| Nov 12, 2025 | -$ 1.17 | $ 201.16 | $ 206.45 | |
| Aug 7, 2025 | -$ 0.93 | $ 182.60 | $ 191.49 | |
| May 1, 2025 | -$ 1.66 | $ 170.44 | $ 172.06 | |
| Feb 12, 2025 | -$ 0.68 | $ 119.51 | $ 142.49 | |
| Nov 14, 2024 | -$ 1.81 | $ 126.03 | $ 126.51 | |
| Sep 3, 2024 | -$ 2.05 | $ 138.45 | $ 119.50 | |
| May 2, 2024 | -$ 2.48 | $ 141.01 | $ 137.20 | |
| Feb 7, 2024 | -$ 1.66 | $ 140.84 | $ 139.25 | |
| Nov 7, 2023 | -$ 3.08 | $ 94.41 | $ 94.74 | |
| Sep 5, 2023 | -$ 2.35 | $ 98.27 | $ 103.97 | |
| Apr 27, 2023 | -$ 2.18 | $ 76.44 | $ 69.96 | |
| Feb 16, 2023 | -$ 3.96 | $ 112.00 | $ 116.65 | |
| Nov 2, 2022 | -$ 3.05 | $ 116.71 | $ 119.78 | |
| Aug 10, 2022 | -$ 1.50 | $ 93.15 | $ 104.81 | |
| May 11, 2022 | -$ 2.31 | $ 82.64 | $ 80.01 | |
| Mar 2, 2022 | -$ 2.06 | $ 108.83 | $ 105.52 |
Ascendis Pharma A/S released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Ascendis Pharma A/S beat analysts’ expectations during the last earnings period by
